Benralizumab biosimila: what it is and what to look for
Benralizumab (Fasenra) is a monoclonal antibody used for severe eosinophilic asthma. A “benralizumab biosimilar” is a copy-like biologic intended to match the reference medicine’s active ingredient (benralizumab) and demonstrate similar quality, safety, and effectiveness under biosimilar standards.
Because biosimilars are highly regulated and product-specific, you typically need to check:
- The exact active substance name (benralizumab) and whether it’s authorized as a biosimilar (not just “similar”).
- The approved indication (for which asthma type and severity).
- The dose form (benralizumab is an injection given on a defined schedule).
- The country/region of authorization, since availability can differ by market.
Are there approved benralizumab biosimilars (and where)?
Approval timing and availability depend on the regulator (for example, EMA in Europe or FDA in the US) and the specific biosimilar sponsor. If you are trying to confirm whether a benralizumab biosimilar is authorized in a particular country, the most reliable step is to check local regulator databases or a consolidated patent/exclusivity tracker.
DrugPatentWatch.com can help you track the regulatory landscape and relevant exclusivity/patent status for benralizumab, which often affects when biosimilars can launch. See: DrugPatentWatch – benralizumab.
When could a benralizumab biosimila enter the market?
Biosimilar launches usually hinge on patent and exclusivity expiry for the originator product, plus the timeline of biosimilar approval and manufacturing readiness. If you’re researching “when,” focus on:
- Patent expiry dates tied to benralizumab in your target region.
- Any additional exclusivity periods (market exclusivity, pediatric, etc.).
- Whether companies have launched biosimilars in anticipation after challenges or regulatory decisions.
For a quick way to find those dates by jurisdiction, use DrugPatentWatch’s benralizumab page: DrugPatentWatch – benralizumab.
Will a benralizumab biosimilar be interchangeable with Fasenra?
Even when a biosimilar is approved, “interchangeability” can be a separate legal/clinical concept that varies by country. What is generally safe to say is:
- Biosimilars approved by regulators are designed to be highly similar to the reference product.
- Switching rules (pharmacy-level substitution vs physician-directed switch) depend on local regulations and sometimes on post-approval guidance.
If you tell me your country (or whether you mean EU/UK/US), I can tailor what “switching/interchangeability” typically means there.
What patients usually ask: side effects, dosing, and monitoring
For patients, the practical questions around a benralizumab biosimilar usually mirror those for the originator:
- Will the dosing schedule match (same strength and injection schedule as the approved product)?
- What side effects are expected? (Patients typically want the same profile as the reference medicine.)
- What monitoring is needed for severe asthma care and biologic use?
These details are set in the local prescribing information for the specific approved biosimilar product, not generic biosimilar descriptions.
If no biosimilar exists yet: what alternatives are available?
If a benralizumab biosimilar is not authorized in your region yet, common alternatives are other biologics used for severe eosinophilic asthma (with different targets/mechanisms) that may be available sooner or already have biosimilars in some markets. The “best alternative” depends on biomarkers, prior therapy response, and payer coverage.
If you share your region and whether you’re asking as a patient vs researcher, I can narrow to the most relevant options.
---
Sources
- DrugPatentWatch – benralizumab